Railway Pension Investments Ltd Has $189.45 Million Stake in IDEXX Laboratories, Inc. $IDXX

Railway Pension Investments Ltd raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 92.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 296,530 shares of the company’s stock after buying an additional 142,200 shares during the period. IDEXX Laboratories comprises approximately 2.6% of Railway Pension Investments Ltd’s portfolio, making the stock its 8th largest position. Railway Pension Investments Ltd owned about 0.37% of IDEXX Laboratories worth $189,450,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of IDXX. Armstrong Advisory Group Inc. boosted its holdings in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares during the period. Opal Wealth Advisors LLC bought a new stake in IDEXX Laboratories in the second quarter valued at approximately $29,000. Salomon & Ludwin LLC bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $35,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $30,000. Finally, Ameritas Advisory Services LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $669.99 on Monday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The company has a 50 day moving average price of $699.69 and a 200-day moving average price of $638.31. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The firm has a market capitalization of $53.50 billion, a PE ratio of 53.13, a P/E/G ratio of 3.58 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the firm posted $2.80 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Monday, December 29th. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Barclays started coverage on shares of IDEXX Laboratories in a research note on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective for the company. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.